Serial Number
88981530
Owner
CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLCAttorney
Joshua M. Gerben, Esq.First Use Date
Mar 16, 2021
Filing Date
Dec 12, 2019
CENTER FOR BREAKTHROUGH MEDICINES Trademark
Serial Number: 88981530 • Registration: 6382057
Trademark Classes
Owner Contact Info
411 SWEDELAND ROAD
KING OF PRUSSIA, PA 19406
Entity Type: 16
Legal Representation
Correspondence Address
Joshua M. Gerben, Esq. GERBEN LAW FIRM, PLLC
SUITE 500
1050 CONNECTICUT AVE. NW
WASHINGTON, DC 20036
UNITED STATES
Trademark Details
Filing Date
December 12, 2019
Registration Date
June 8, 2021
First Use Anywhere
March 16, 2021
First Use in Commerce
March 16, 2021
Published for Opposition
January 12, 2021
Goods & Services
Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting
Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research
